Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Cheryl P Ferrufino, Julie Munakata, Wenhui Wei, Clare Proudfoot, Andreas Kuznik, Susan H Boklage & Chieh-I Chen. (2018) Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. ClinicoEconomics and Outcomes Research 10, pages 805-819.
Read now
Read now
Brian C. Sauer, Chia-Chen Teng, Tao He, Jianwei Leng, Chao-Chin Lu, Jessica A. Walsh, Neel Shah, David J. Harrison, Derek H. Tang & Grant W. Cannon. (2016) Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. Journal of Medical Economics 19:1, pages 34-43.
Read now
Read now
Ning Wu, Sharvari Bhurke, Neel Shah & David J Harrison. (2015) Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. ClinicoEconomics and Outcomes Research 7, pages 257-266.
Read now
Read now
Diego Sangiorgi, Maurizio Benucci, Carmela Nappi, Valentina Perrone, Stefano Buda & Luca Degli Esposti. (2015) Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics: Targets and Therapy 9, pages 119-127.
Read now
Read now
Julio Martinez-Cutillas, Carme Alerany-Pardo, Joaquín Borrás-Blasco, Antonio Broto-Sumalla, Amparo Burgos-SanJosé, Consuelo Climent-Bolta, Vicente Escudero-Vilaplana, María Anunciación Fernández-Fuente, Mónica Ferrit-Martin, Pilar Gómez-Germá, José Manuel Martínez-Sesmero, Jesús Mayorga-Pérez, Belén Menchén-Viso, Javier Merino-Alonso, Josefa Polache-Vengud & Amelia Sánchez-Guerrero. (2015) The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Expert Review of Pharmacoeconomics & Outcomes Research 15:5, pages 851-858.
Read now
Read now
Joaquín Borrás-Blasco & Andres Navarro Ruiz. (2015) Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 71-79.
Read now
Read now
Articles from other publishers (10)
Xuan Tang, Zehao Liu, Zhihua Yang, Shengmei Xu, Maojie Wang, Xiumin Chen, Zehuai Wen & Runyue Huang. (2021) The Effect of Chinese Medicine Compound in the Treatment of Rheumatoid Arthritis on the Level of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Bon San Koo, Yu-Cheol Lim, Min-Young Lee, Ja-Young Jeon, Hyun-Jeong Yoo, In-Sun Oh, Ju-Young Shin & Tae-Hwan Kim. (2021) Dose Reduction of Tumor Necrosis Factor Inhibitor and its Effect on Medical Costs for Patients with Ankylosing Spondylitis. Rheumatology and Therapy 8:1, pages 347-359.
Crossref
Crossref
Stanley B. Cohen, Joel M. Kremer, Kimberly J. Dandreo, George W. Reed, Robert Magner, Ying Shan, Shelly Kafka, Raphael J. DeHoratius, Lorie Ellis & Dennis Parenti. (2019) Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. Clinical Rheumatology 38:9, pages 2501-2508.
Crossref
Crossref
Sergio Schwartzman, Yunfeng Li, Huanxue Zhou & Jacqueline B. Palmer. (2017) Economic impact of biologic utilization patterns in patients with psoriatic arthritis. Clinical Rheumatology 36:7, pages 1579-1588.
Crossref
Crossref
Tao Gu, Neel Shah, Gaurav Deshpande, Derek H. Tang & Debra F. Eisenberg. (2016) Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study. Drugs - Real World Outcomes 3:4, pages 369-381.
Crossref
Crossref
Gundula Krack, Henning Zeidler & Jan Zeidler. (2016) Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods. Drugs - Real World Outcomes 3:3, pages 265-278.
Crossref
Crossref
José Andrés Román Ivorra, José Ivorra, Emilio Monte-Boquet, Cristina Canal, Itziar Oyagüez & Manuel Gómez-Barrera. (2016) Cost Analysis of Biologic Drugs in Rheumatoid Arthritis First Line Treatment After Methotrexate Failure According to Patients’ Body Weight. Reumatología Clínica (English Edition) 12:3, pages 123-129.
Crossref
Crossref
José Andrés Román Ivorra, José Ivorra, Emilio Monte-Boquet, Cristina Canal, Itziar Oyagüez & Manuel Gómez-Barrera. (2016) Análisis de costes de la utilización de fármacos biológicos para la artritis reumatoide en primera línea de tratamiento tras respuesta inadecuada a metotrexato en función del peso de los pacientes. Reumatología Clínica 12:3, pages 123-129.
Crossref
Crossref
Morgane Beck, Michel Velten, Marie-Christine Rybarczyk-Vigouret, José Covassin, Christelle Sordet & Bruno Michel. (2015) Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace. Drugs - Real World Outcomes 2:3, pages 205-215.
Crossref
Crossref
Rafael Ferriols-Lisart & Francisco Ferriols-Lisart. (2015) Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatology International 35:7, pages 1193-1210.
Crossref
Crossref